GORE VIABAHN Endoprosthesis With Heparin Bioactive Surface in the Treatment of SFA Obstructive Disease (VIPER)

Completed · Not applicable

Conditions studied: Peripheral Vascular Diseases

In brief

The objective of the study is collect data on the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface in the treatment of chronic Superficial Femoral Artery disease. Device patency at 12 months is the primary endpoint.

Key facts

Study ID

NCT00541307

Run by

W.L.Gore & Associates

People needed

119

Starts

2007-10-01

Expected to finish

2011-06-01

Last updated by the study team

2012-12-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Tri-City Medical Center — Oceanside, California, United States
• Mercy Hospital and Medical Center — Chicago, Illinois, United States
• Columbia Surgical Associates — Columbia, Missouri, United States
• Baylor University Medical Center — Dallas, Texas, United States
• St. Luke's Medical Center — Milwaukee, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.